Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Zynerba Pharmaceuticals, Inc. (ZYNE)

0.4302   -0.025 (-5.45%) 03-24 16:00
Open: 0.41 Pre. Close: 0.455
High: 0.448 Low: 0.41
Volume: 81,458 Market Cap: 20(M)

Technical analysis

as of: 2023-03-24 4:31:47 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.57     One year: 0.65
Support: Support1: 0.38    Support2: 0.32
Resistance: Resistance1: 0.49    Resistance2: 0.56
Pivot: 0.44
Moving Average: MA(5): 0.46     MA(20): 0.45
MA(100): 0.56     MA(250): 0.9
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 56.1     %D(3): 68.3
RSI: RSI(14): 41.7
52-week: High: 2.15  Low: 0.38
Average Vol(K): 3-Month: 324 (K)  10-Days: 260 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ZYNE ] has closed above bottom band by 40.3%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.45 - 0.45 0.45 - 0.45
Low: 0.4 - 0.41 0.41 - 0.41
Close: 0.43 - 0.43 0.43 - 0.43

Company Description

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Headline News

Thu, 23 Mar 2023
What is Wall Street's Target Price for Zynerba Pharmaceuticals Inc (ZYNE) Stock Thursday? - InvestorsObserver

Tue, 21 Mar 2023
North American Morning Briefing : Stock Futures -2- -

Mon, 13 Mar 2023
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank -

Thu, 09 Mar 2023
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd ... - MyChesCo

Tue, 07 Mar 2023
Where Will Zynerba Pharmaceuticals Inc (ZYNE) Stock Go Next After It Is Lower By 0.00% in a Week? - InvestorsObserver

Tue, 07 Mar 2023
North American Morning Briefing: Stocks Seen on -2- - Morningstar

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 47 (M)
Shares Float 42 (M)
% Held by Insiders 5.2 (%)
% Held by Institutions 18.6 (%)
Shares Short 182 (K)
Shares Short P.Month 76 (K)

Stock Financials

EPS -1
EPS Est Next Qtl -0.58
EPS Est This Year -2.43
EPS Est Next Year -2.4
Book Value (p.s.) 1.16
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -29.1
Return on Equity (ttm) -54.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.75
Qtrly Earnings Growth 0
Operating Cash Flow -25 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio -0.44
PEG Ratio 0
Price to Book value 0.36
Price to Sales 0
Price to Cash Flow -0.81

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.